These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
482 related articles for article (PubMed ID: 31933158)
1. The Battle Is on: New Beta-Lactams for the Treatment of Multidrug-Resistant Gram-Negative Organisms. Noval M; Banoub M; Claeys KC; Heil E Curr Infect Dis Rep; 2020 Jan; 22(1):1. PubMed ID: 31933158 [TBL] [Abstract][Full Text] [Related]
2. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199 [TBL] [Abstract][Full Text] [Related]
3. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents. Bader MS; Loeb M; Leto D; Brooks AA Postgrad Med; 2020 Apr; 132(3):234-250. PubMed ID: 31608743 [TBL] [Abstract][Full Text] [Related]
4. Genome characterization of a Klebsiella pneumoniae co-producing OXA-181 and KPC-121 resistant to ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam and cefiderocol isolated from a critically ill patient. Gaibani P; Amadesi S; Lazzarotto T; Ambretti S J Glob Antimicrob Resist; 2022 Sep; 30():262-264. PubMed ID: 35777673 [TBL] [Abstract][Full Text] [Related]
5. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations. Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684 [TBL] [Abstract][Full Text] [Related]
6. Epidemiology and In Vitro Activity of Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam against Bovo F; Lombardo D; Lazzarotto T; Ambretti S; Gaibani P Antibiotics (Basel); 2022 Nov; 11(11):. PubMed ID: 36421265 [TBL] [Abstract][Full Text] [Related]
7. Last resort beta-lactam antibiotics for treatment of New-Delhi Metallo-Beta-Lactamase producing Enterobacterales and other Difficult-to-Treat Resistance in Gram-negative bacteria: A real-life study. Larcher R; Laffont-Lozes P; Roger C; Doncesco R; Groul-Viaud C; Martin A; Loubet P; Lavigne JP; Pantel A; Sotto A Front Cell Infect Microbiol; 2022; 12():1048633. PubMed ID: 36544909 [TBL] [Abstract][Full Text] [Related]
8. Update of clinical application in ceftazidime-avibactam for multidrug-resistant Gram-negative bacteria infections. Zhen S; Wang H; Feng S Infection; 2022 Dec; 50(6):1409-1423. PubMed ID: 35781869 [TBL] [Abstract][Full Text] [Related]
9. Successful Treatment of Bloodstream Infection due to a KPC-Producing Klebsiella Pneumoniae Resistant to Imipenem/Relebactam in a Hematological Patient. Gaibani P; Bussini L; Amadesi S; Bartoletti M; Bovo F; Lazzarotto T; Viale P; Ambretti S Microorganisms; 2022 Apr; 10(4):. PubMed ID: 35456827 [TBL] [Abstract][Full Text] [Related]
10. Review of novel β-lactams and β-lactam/β-lactamase inhibitor combinations with implications for pediatric use. Olney KB; Thomas JK; Johnson WM Pharmacotherapy; 2023 Jul; 43(7):713-731. PubMed ID: 36825478 [TBL] [Abstract][Full Text] [Related]
11. Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens. Karaiskos I; Galani I; Souli M; Giamarellou H Expert Opin Drug Metab Toxicol; 2019 Feb; 15(2):133-149. PubMed ID: 30626244 [TBL] [Abstract][Full Text] [Related]
12. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms. Sharma R; Park TE; Moy S Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862 [TBL] [Abstract][Full Text] [Related]
13. In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates. Gaibani P; Lewis RE; Volpe SL; Giannella M; Campoli C; Landini MP; Viale P; Re MC; Ambretti S Int J Infect Dis; 2017 Dec; 65():1-3. PubMed ID: 28951106 [TBL] [Abstract][Full Text] [Related]
14. New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn? Wright H; Bonomo RA; Paterson DL Clin Microbiol Infect; 2017 Oct; 23(10):704-712. PubMed ID: 28893690 [TBL] [Abstract][Full Text] [Related]
15. Review of Ceftazidime-Avibactam, Meropenem-Vaborbactam, and Imipenem/Cilastatin-Relebactam to Target Hayden DA; White BP; Bennett KK J Pharm Technol; 2020 Oct; 36(5):202-210. PubMed ID: 34752560 [No Abstract] [Full Text] [Related]